9月17日，Tempus AI盘中上涨5.39%，报76.5美元/股，成交额1.75亿美元，延续近期强势上行趋势。
消息面上，公司近期利好密集释放。9月11日，Tempus AI宣布将构建全球最大规模的多模态全基因组数据集，首批涵盖10万条全基因组序列及纵向临床数据，长期目标扩展至100万条，预计中期向公众开放。9月10日，公司获美国高级卫生研究计划局（ARPA-H）最高950万美元资助，用于开发心脏病学领域自主AI代理系统。此外，瑞银近期以70美元目标价启动覆盖，Cantor Fitzgerald给予增持评级及80美元目标价。叠加此前FDA批准其AI肺动脉高压检测产品及Q2业绩超预期，多重催化因素共振推动股价突破主流分析师目标价区间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.